196 related articles for article (PubMed ID: 19755984)
1. Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors.
Flågeng MH; Moi LL; Dixon JM; Geisler J; Lien EA; Miller WR; Lønning PE; Mellgren G
Br J Cancer; 2009 Oct; 101(8):1253-60. PubMed ID: 19755984
[TBL] [Abstract][Full Text] [Related]
2. Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers.
Flågeng MH; Larionov A; Geisler J; Knappskog S; Prestvik WS; Bjørkøy G; Lilleng PK; Dixon JM; Miller WR; Lønning PE; Mellgren G
J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt B):228-235. PubMed ID: 27343990
[TBL] [Abstract][Full Text] [Related]
3. Coactivation of liver receptor homologue-1 by peroxisome proliferator-activated receptor gamma coactivator-1alpha on aromatase promoter II and its inhibition by activated retinoid X receptor suggest a novel target for breast-specific antiestrogen therapy.
Safi R; Kovacic A; Gaillard S; Murata Y; Simpson ER; McDonnell DP; Clyne CD
Cancer Res; 2005 Dec; 65(24):11762-70. PubMed ID: 16357189
[TBL] [Abstract][Full Text] [Related]
4. Modulation of hepatocyte nuclear factor-4alpha function by the peroxisome-proliferator-activated receptor-gamma co-activator-1alpha in the acute-phase response.
Wang Z; Burke PA
Biochem J; 2008 Oct; 415(2):289-96. PubMed ID: 18510493
[TBL] [Abstract][Full Text] [Related]
5. Co-expression of steroid receptors (estrogen receptor alpha and/or progesterone receptors) and Her-2/neu: Clinical implications.
Ciocca DR; Gago FE; Fanelli MA; Calderwood SK
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):32-40. PubMed ID: 17049840
[TBL] [Abstract][Full Text] [Related]
6. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.
Osborne CK; Bardou V; Hopp TA; Chamness GC; Hilsenbeck SG; Fuqua SA; Wong J; Allred DC; Clark GM; Schiff R
J Natl Cancer Inst; 2003 Mar; 95(5):353-61. PubMed ID: 12618500
[TBL] [Abstract][Full Text] [Related]
7. Interleukin enhancer-binding factor 3 functions as a liver receptor homologue-1 co-activator in synergy with the nuclear receptor co-activators PRMT1 and PGC-1α.
Ohno M; Komakine J; Suzuki E; Nishizuka M; Osada S; Imagawa M
Biochem J; 2011 Aug; 437(3):531-40. PubMed ID: 21554248
[TBL] [Abstract][Full Text] [Related]
8. Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer.
Yamashita H; Takahashi S; Ito Y; Yamashita T; Ando Y; Toyama T; Sugiura H; Yoshimoto N; Kobayashi S; Fujii Y; Iwase H
Cancer Sci; 2009 Nov; 100(11):2028-33. PubMed ID: 19659610
[TBL] [Abstract][Full Text] [Related]
9. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
Howell A; Howell SJ; Clarke R; Anderson E
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S; Gallo C; De Laurentiis M; Bisagni G; Arpino G; Sarobba MG; Riccardi F; Russo A; Del Mastro L; Cogoni AA; Cognetti F; Gori S; Foglietta J; Frassoldati A; Amoroso D; Laudadio L; Moscetti L; Montemurro F; Verusio C; Bernardo A; Lorusso V; Gravina A; Moretti G; Lauria R; Lai A; Mocerino C; Rizzo S; Nuzzo F; Carlini P; Perrone F;
Lancet Oncol; 2018 Apr; 19(4):474-485. PubMed ID: 29482983
[TBL] [Abstract][Full Text] [Related]
11. ErbB receptor signaling and therapeutic resistance to aromatase inhibitors.
Shin I; Miller T; Arteaga CL
Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1008s-1012s. PubMed ID: 16467117
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of aromatase inhibitors and antiestrogens on estrogen receptor expression in breast cancer cells.
Smollich M; Götte M; Fischgräbe J; Radke I; Kiesel L; Wülfing P
Anticancer Res; 2009 Jun; 29(6):2167-71. PubMed ID: 19528477
[TBL] [Abstract][Full Text] [Related]
13. Estrogen-related receptor-gamma and peroxisome proliferator-activated receptor-gamma coactivator-1alpha regulate estrogen-related receptor-alpha gene expression via a conserved multi-hormone response element.
Liu D; Zhang Z; Teng CT
J Mol Endocrinol; 2005 Apr; 34(2):473-87. PubMed ID: 15821111
[TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor and interleukin 1 decrease RXRalpha, PPARalpha, PPARgamma, LXRalpha, and the coactivators SRC-1, PGC-1alpha, and PGC-1beta in liver cells.
Kim MS; Sweeney TR; Shigenaga JK; Chui LG; Moser A; Grunfeld C; Feingold KR
Metabolism; 2007 Feb; 56(2):267-79. PubMed ID: 17224343
[TBL] [Abstract][Full Text] [Related]
15. Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinoma-specific co-activator.
Hudelist G; Czerwenka K; Kubista E; Marton E; Pischinger K; Singer CF
Breast Cancer Res Treat; 2003 Mar; 78(2):193-204. PubMed ID: 12725419
[TBL] [Abstract][Full Text] [Related]
16. Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer.
Myers E; Hill AD; Kelly G; McDermott EW; O'Higgins NJ; Buggy Y; Young LS
Clin Cancer Res; 2005 Mar; 11(6):2111-22. PubMed ID: 15788656
[TBL] [Abstract][Full Text] [Related]
17. Is tamoxifen the Rosetta stone for breast cancer?
Jordan VC
J Natl Cancer Inst; 2003 Mar; 95(5):338-40. PubMed ID: 12618491
[No Abstract] [Full Text] [Related]
18. PGC-1α promotes the growth of ErbB2/Neu-induced mammary tumors by regulating nutrient supply.
Klimcakova E; Chénard V; McGuirk S; Germain D; Avizonis D; Muller WJ; St-Pierre J
Cancer Res; 2012 Mar; 72(6):1538-46. PubMed ID: 22266114
[TBL] [Abstract][Full Text] [Related]
19. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
